Personalis, Inc. is a growing cancer genomics company transforming the development of next generation therapies by providing more comprehensive molecular data about each patient’s cancer. To address an increasingly complex understanding of cancer, the Company has developed a more comprehensive platform for analyzing a patient’s tumor and its associated immune microenvironment, to enable various applications including the development of more efficacious therapeutics. Personalis designed its flagship NeXT platform to provide biopharmaceutical customers with information from a limited tumor tissue sample on all of the approximately 20,000 human genes, together with the immune system, in contrast to many currently marketed “hotspot” panels that cover a limited range of only ~50 to ~500 genes and do not address the immune repertoire.